Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units.
The purpose of this study was to determine the risk factors for sepsis, the causative organisms, and mortality following infection in a large and diverse sample of NICUs, and to conclude that overall mortality in VLBW infants with early- and late-onset sepsi is higher than in infants with negative cultures. Expand
Nomenclature for human CYP2D6 alleles.
It is proposed that alleles be designated by CYP2D6 followed by an asterisk and a combination of roman letters and arabic numerals distinct for each allele with the number specifying the key mutation and, where appropriate, a letter specifying additional mutations. Expand
CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
The data suggest that the N-demethylation of dextromethorphan is dependent on CYP3A and that both CYP2D6 and CYP 3A are involved in the overall metabolism of deXTromethmorphan. Expand
Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes.
- F. Berthou, B. Guillois, C. Riché, Y. Dréano, É. Jacqz-Aigrain, P. Beaune
- Biology, Medicine
- Xenobiotica; the fate of foreign compounds in…
- 1 June 1992
All in vitro data indicate that paraxanthine formation is mediated mainly by P4501A1 and 1A2 in mammals while theophyllines formation ismediated mainly by cytochromes P-450 other than those of the 1A family. Expand
Expression of CYP2D6 in developing human liver.
- J. Treluyer, É. Jacqz-Aigrain, F. Alvarez, T. Cresteil
- Biology, Medicine
- European journal of biochemistry
- 1 December 1991
The rise in CYP2D6 protein was associated with the developmental onset of dextromethorphan O-dem methylation, but not N-demethylation, even if activity was lower in fetal than in neonatal and in adult liver microsomes, suggesting that regulation is primarily at the transcriptional level, but cannot rule out the participation of post-transcriptional events in the regulation process throughout ontogenesis. Expand
LOCALIZATION AND mRNA EXPRESSION OF CYP3A AND P-GLYCOPROTEIN IN HUMAN DUODENUM AS A FUNCTION OF AGE
- M. Fakhoury, C. Litalien, +4 authors É. Jacqz-Aigrain
- Biology, Medicine
- Drug Metabolism and Disposition
- 1 November 2005
It is shown that neonates and infants had a significant expression of CYP3A and P-gp mRNA in the intestine, suggesting a different maturation profile of CYp3Aand P- gp with age in the liver and the intestine. Expand
Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
- T. Adam de Beaumais, M. Fakhoury, +4 authors É. Jacqz-Aigrain
- British journal of clinical pharmacology
- 1 April 2011
Age and both TPMT and ITPA genotypes influenced 6-MP metabolism and high 6-MMPN was associated with hepatotoxicity and should be used to monitor ALL treatment in children. Expand
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
- W. Zhao, V. Elie, +11 authors É. Jacqz-Aigrain
- Clinical pharmacology and therapeutics
- 1 December 2009
The population pharmacokinetic–pharmacogenetic model developed in de novo pediatric kidney transplant patients demonstrated that, in children, tacrolimus dosage should be based on weight, hematocrit levels, and CYP3A5 polymorphism. Expand
Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age
- C. Ganiere-Monteil, Y. Médard, +5 authors É. Jacqz-Aigrain
- European Journal of Clinical Pharmacology
- 12 March 2004
No impact of child development on TPMT activity could be evidenced, suggesting that T PMT activity is already mature at birth, highlighting the importance of measuring TPMt activity to detect all patients at risk of thiopurine toxicity. Expand
Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration.
- É. Jacqz-Aigrain, W. Zhao, M. Sharland, J. N. van den Anker
- Seminars in fetal & neonatal medicine
- 1 February 2013
The goal of optimising vancomycin therapy in the neonate is highlighted and future research directions are discussed, with specific attention given to dosing optimisation of vancomYcin to avoid resistance and maximise the likelihood of achieving the therapeutic target. Expand